Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

被引：0
|
作者：
Sanchez Gonzalez, J. C. [1 ]
Nunez Garcia, B. [1 ]
Blanco Clemente, M. [1 ]
Calvo de Juan, V. [1 ]
Cantos Sanchez de Ibarguen, B. [1 ]
Mendez Garcia, M. [1 ]
Aguado Noya, R. [1 ]
Ruiz de Domingo, D. [1 ]
Gonzalez Sanchez, A. [1 ]
Provencio, M. [1 ]
机构：
[1] Hosp Univ Puerta Hierro, Majadahonda, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Immunotherapy; Advanced disease; Real World Data;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-06
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [31] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    Filippi, A. R.
    Bar, J.
    Chouaid, C.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido, P.
    Haakensen, V. D.
    Kao, S.
    Markman, B.
    Mcdonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    Sibille, A.
    Siva, S.
    Heuvel, M. van den
    Vercauter, P.
    Anand, S.
    Chander, P.
    Licour, M.
    Lima, A. R. de
    Qiao, Y.
    Girard, N.
    ESMO OPEN, 2024, 9 (06)
  • [32] From clinical trials to clinical practice: Real-life outcome data of everolimus and exemestane in the treatment of patients with metastatic breast cancer
    Abdel-Razeq, Hikmat
    Sharaf, Baha'
    Abdulelah, Hazem
    Inserat, Bayan
    Al-Tell, Abdallah
    Salam, Mourad
    Bater, Rayan
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
    Brat, Kristian
    Bratova, Monika
    Skrickova, Jana
    Barinova, Magda
    Hurdalkova, Karolina
    Pesek, Milos
    Havel, Libor
    Koubkova, Leona
    Hrnciarik, Michal
    Krejci, Jana
    Fischer, Ondrej
    Zemanova, Milada
    Coupkova, Helena
    Svaton, Martin
    THORACIC CANCER, 2020, 11 (11) : 3346 - 3356
  • [34] Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV- data from the Czech TULUNG Registry
    Brat, Kristian
    Bratova, Monika
    Skrickova, Jana
    Barinova, Magda
    Hurdalkova, Karolina
    Pesek, Milos
    Svaton, Martin
    Havel, Libor
    Cernovska, Marketa
    Koubkova, Leona
    Hrnciarik, Michal
    Krejci, Jana
    Kultan, Juraj
    Fischer, Ondrej
    Zemanova, Milada
    Coupkova, Helena
    Tuzova, Tana
    Dolezal, Daniel
    Safanda, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [35] First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice
    Pol, S.
    Lampertico, P.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (06) : 377 - 386
  • [36] LESS THAN 5% OF REAL-LIFE PATIENTS WHO SWITCH FROM IV TO SC ABATACEPT IN REAL-WORLD CLINICAL PRACTICE SUBSEQUENTLY SWITCH BACK TO THE IV FORMULATION
    Alten, R.
    Lorenz, H-M.
    Mariette, X.
    Nuesslein, H.
    Galeazzi, M.
    Navarro, F.
    Chartier, M.
    Heitzmann, J.
    Rauch, C.
    Le Bars, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1193 - 1194
  • [37] Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
    Lakdawalla, Darius N.
    Shafrin, Jason
    Hou, Ningqi
    Peneva, Desi
    Vine, Seanna
    Park, Jinhee
    Zhang, Jie
    Brookmeyer, Ron
    Figlin, Robert A.
    VALUE IN HEALTH, 2017, 20 (07) : 866 - 875
  • [38] What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice
    Carbo, Adrian Valls
    Beltran, Alvaro
    Roman, Irene Sanchez-Miranda
    Cabal, Borja
    Gomez-Porro, Pablo
    Aledo-Serrano, Angel
    Sobrino, Gloria Lopez
    Ayuga, Fernando
    Eguilaz, Maria Gomez
    Gil-Nagel, Antonio
    EPILEPSY & BEHAVIOR, 2024, 151
  • [39] ENLARGE Lung: Observational data on overall survival, safety and quality of life of 882 patients with locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC) treated with nivolumab in Germany
    Schumann, C.
    Groeschel, A.
    Guetz, S.
    Schulz, H.
    Mueller-Huesmann, H.
    Liersch, R.
    von der Heyde, E.
    Waldenberger, D.
    Sebastian, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 150 - 150
  • [40] RETROSPECTIVE COMPARISON OF REAL-LIFE SURVIVAL DATA FROM SINGLE CENTRE TRIALS - THE CLINICAL OUTCOME OF VEMURAFENIB THERAPY IN METASTATIC MELANOMA PATIENTS
    Porneczy, E.
    Czirbesz, K.
    Toth, E.
    Liszkay, G.
    Boncz, I
    VALUE IN HEALTH, 2015, 18 (07) : A441 - A441
12345